Metformin represses self-renewal of the human breast carcinoma stem cells via inhibition of estrogen receptor-mediated OCT4 expression
- PMID: 22132214
- PMCID: PMC3223228
- DOI: 10.1371/journal.pone.0028068
Metformin represses self-renewal of the human breast carcinoma stem cells via inhibition of estrogen receptor-mediated OCT4 expression
Abstract
Metformin, a Type II diabetic treatment drug, which inhibits transcription of gluconeogenesis genes, has recently been shown to lower the risk of some diabetes-related tumors, including breast cancer. Recently, "cancer stem cells" have been demonstrated to sustain the growth of tumors and are resistant to therapy. To test the hypothesis that metformin might be reducing the risk to breast cancers, the human breast carcinoma cell line, MCF-7, grown in 3-dimensional mammospheres which represent human breast cancer stem cell population, were treated with various known and suspected breast cancer chemicals with and without non-cytotoxic concentrations of metformin. Using OCT4 expression as a marker for the cancer stem cells, the number and size were measured in these cells. Results demonstrated that TCDD (100 nM) and bisphenol A (10 µM) increased the number and size of the mammospheres, as did estrogen (10 nM E2). By monitoring a cancer stem cell marker, OCT4, the stimulation by these chemicals was correlated with the increased expression of OCT4. On the other hand, metformin at 1 and 10 mM concentration dramatically reduced the size and number of mammospheres. Results also demonstrated the metformin reduced the expression of OCT4 in E2 & TCDD mammospheres but not in the bisphenol A mammospheres, suggesting different mechanisms of action of the bisphenol A on human breast carcinoma cells. In addition, these results support the use of 3-dimensional human breast cancer stem cells as a means to screen for potential human breast tumor promoters and breast chemopreventive and chemotherapeutic agents.
Conflict of interest statement
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3223228/bin/pone.0028068.g001.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3223228/bin/pone.0028068.g002.gif)
![Figure 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3223228/bin/pone.0028068.g003.gif)
![Figure 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3223228/bin/pone.0028068.g004.gif)
![Figure 5](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3223228/bin/pone.0028068.g005.gif)
![Figure 6](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3223228/bin/pone.0028068.g006.gif)
Similar articles
-
Characterization of the stemness potency of mammospheres isolated from the breast cancer cell lines.Tumour Biol. 2019 Aug;41(8):1010428319869101. doi: 10.1177/1010428319869101. Tumour Biol. 2019. PMID: 31423948
-
Evaluation of Melatonin Effect on Human Breast Cancer Stem Cells Using a Threedimensional Growth Method of Mammospheres.Anticancer Agents Med Chem. 2017;17(7):961-965. doi: 10.2174/1871520616666160923093229. Anticancer Agents Med Chem. 2017. PMID: 27671309
-
Reduced tumorigenicity and drug resistance through the downregulation of octamer-binding protein 4 and Nanog transcriptional factor expression in human breast stem cells.Mol Med Rep. 2015 Mar;11(3):1647-54. doi: 10.3892/mmr.2014.2972. Epub 2014 Nov 18. Mol Med Rep. 2015. PMID: 25405855 Free PMC article.
-
Metformin may function as anti-cancer agent via targeting cancer stem cells: the potential biological significance of tumor-associated miRNAs in breast and pancreatic cancers.Ann Transl Med. 2014 Jun;2(6):59. doi: 10.3978/j.issn.2305-5839.2014.06.05. Ann Transl Med. 2014. PMID: 25333034 Free PMC article. Review.
-
Down-regulation of vitamin D receptor in mammospheres: implications for vitamin D resistance in breast cancer and potential for combination therapy.PLoS One. 2013;8(1):e53287. doi: 10.1371/journal.pone.0053287. Epub 2013 Jan 14. PLoS One. 2013. PMID: 23341935 Free PMC article.
Cited by
-
Dynamic interplay of nuclear receptors in tumor cell plasticity and drug resistance: Shifting gears in malignant transformations and applications in cancer therapeutics.Cancer Metastasis Rev. 2024 Mar;43(1):321-362. doi: 10.1007/s10555-024-10171-0. Epub 2024 Mar 22. Cancer Metastasis Rev. 2024. PMID: 38517618 Review.
-
Unlocking the secrets: exploring the influence of the aryl hydrocarbon receptor and microbiome on cancer development.Cell Mol Biol Lett. 2024 Mar 6;29(1):33. doi: 10.1186/s11658-024-00538-0. Cell Mol Biol Lett. 2024. PMID: 38448800 Free PMC article. Review.
-
Cancer stem cells: a target for overcoming therapeutic resistance and relapse.Cancer Biol Med. 2023 Dec 29;20(12):985-1020. doi: 10.20892/j.issn.2095-3941.2023.0333. Online ahead of print. Cancer Biol Med. 2023. PMID: 38164743 Free PMC article. Review.
-
Aryl hydrocarbon receptor: An emerging player in breast cancer pathogenesis and its potential as a drug target (Review).Mol Med Rep. 2024 Jan;29(1):11. doi: 10.3892/mmr.2023.13134. Epub 2023 Nov 24. Mol Med Rep. 2024. PMID: 37997818 Free PMC article. Review.
-
Metformin alleviates adriamycin resistance of osteosarcoma by declining YY1 to inhibit MDR1 transcriptional activity.BMC Pharmacol Toxicol. 2023 Oct 12;24(1):50. doi: 10.1186/s40360-023-00685-8. BMC Pharmacol Toxicol. 2023. PMID: 37828612 Free PMC article.
References
-
- Chong CR, Chabner BA. Mysterious metformin. Oncologist. 2009;14:1178–1181. - PubMed
-
- Bosco JL, Antonsen S, Sorensen HT, Pedersen L, Lash TL. Metformin and incident breast cancer among diabetic women: a population-based case-control study in Denmark. Cancer Epidemiol Biomarkers Prev. 2011;20:101–111. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical